Parallel improvement of systolic function with surgical weight loss in patients with heart failure and reduced ejection fraction: a systematic review and patient-level meta-analysis.

Published
January 22, 2022
Journal
Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery
PICOID
62b2fd67
DOI
Citations
6
Keywords
Bariatric surgery, EF, Ejection fraction, HFrEF, Heart failure with reduced ejection fraction, Morbid obesity, NYHA, New York Heart Association, Roux-en-Y gastric bypass, Sleeve Gastrectomy
Copyright
Copyright © 2021 American Society for Bariatric Surgery. Published by Elsevier Inc. All rights reserved.
Patients/Population/Participants

morbidly obese patients with heart failure with reduced ejection fraction

Intervention

bariatric surgery

Comparison

-

Outcome

ejection fraction, New York Heart Association functional class

Abstract

P
I
C
O

Morbid obesity (MO) is an increasingly common condition in patients with heart failure with reduced ejection fraction (HFrEF). Although substantial weight loss in morbidly obese patients has proved to slow the progression of heart failure, parallel alteration of ejection fraction (EF) and New York Heart Association (NYHA) functional class along with post-bariatric surgery weight loss is yet to be determined. This systematic review aimed to measure the effect of bariatric weight loss on EF and NYHA functional class in patients with HFrEF. A systematic literature review was performed in Medline/PubMed to identify studies in patients with MO and pre-existing HFrEF, who underwent bariatric surgery. A total of 11 studies encompassing 136 patients with HFrEF undergoing bariatric surgery for MO were included. Six studies provided patient-level data on 37 cases. Patients lost an average body mass index (BMI) of 12.9 ± 4.2 kg/m Weight loss induced by bariatric surgery results in parallel EF increase in patients with MO and HFrEF. However, current data does not indicate a parallel improvement of clinical symptoms (NYHA functional class) along with such an increase in EF in this population of patients.

Similar article map

CEO: Hwi-yeol YunCOO: Jung-woo ChaeCTO: Sangkeun Jung
Location: 204, W6, Chungnam National University, 99, Daehak-ro, Yuseong-gu, Daejeon, Republic of Korea
Tel: 042-821-7328E-mail: webmaster@lilac-co.kr
Copyright © 2024 by LiLac. All Rights Reserved.